Tech Company Financing Transactions
Anaheim Bio Funding Round
Droia Ventures, Frazier Life Sciences and Novartis Venture Fund participated in a $44.9 million Series A venture round for Anaheim Bio. The round was recorded on 11/5/2026.
Transaction Overview
Company Name
Announced On
11/5/2026
Transaction Type
Venture Equity
Amount
$44,900,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance ANA-1, a small molecule therapeutic candidate for calcium pyrophosphate deposition disease (CPPD), through IND-enabling studies and into Phase 1.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Leiden, Undisclosed
NL
Leiden, Undisclosed
NL
Phone
Undisclosed
Website
Email Address
Overview
Anaheim Bio is a preclinical-stage biotechnology company developing small-molecule therapies for calcium pyrophosphate deposition disease (CPPD), a form of inflammatory arthritis. Its lead drug candidate, ANA-1, is designed to lower extracellular pyrophosphate levels and target the underlying cause of crystal formation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ilan Ganot
Chief Financial Officer
Rick Dekker
Chief Scientific Officer
Matthias Woensel
Browse more venture capital transactions:
Prev: 11/5/2026: T-Therapeutics venture capital transaction
Next: 11/5/2026: Kabilio venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs